Papillomavirus vaccines
AssigneeGeorgetown University
InventorsC. Richard Schlegel, A. Bennett Jenson
Life of this patent
Estimating the term…
Loading patent…
AssigneeGeorgetown University
InventorsC. Richard Schlegel, A. Bennett Jenson
Estimating the term…
Seven polyclonal and monoclonal antibodies were characterized for their ability to react specifically with either conformational or non-conformational epitopes of the HPV-1 virion. Using these antibodies, it was shown that the HPV-1 L1 protein (when expressed by an SV40 vector in cos cells) displayed conformational epitopes characteristic of intact viral particles. In addition, the L1 capsid protein was translocated normally into cell nuclei, was of appropriate size (57kD), and could be isolated in native form by immunoprecipitation techniques. Most importantly, the screening of expressed papillomavirus capsid proteins for reactivity with conformation-dependent antibodies represents a new, general methodology for ensuring that such proteins will be suitable for use in vaccine development or in the serologic detection/typing of human papillomavirus infections.
A method of immunodetecting human papillomavirus antibodies which specifically bind native human papillomavirus L1 protein, comprising:
A diagnostic kit for detecting the presence of antibodies directed against native human papillomavirus L1 protein which comprises:
Dependencies are inferred from the claim text.